Outcomes for women receiving long-acting cabotegravir plus rilpivirine monthly and every two months: ATLAS-2M study Week 48 results

被引：0

作者：

Benn, P. ^{[1
]}

Quercia, R. ^{[2
]}

Hudson, K. ^{[3
]}

Wang, Y. ^{[4
]}

Chounta, V. ^{[5
]}

Talarico, C. ^{[6
]}

Ford, S. ^{[7
]}

Cutrell, A. ^{[8
]}

Margolis, D. ^{[9
]}

Van Solingen-Ristea, R. ^{[10
]}

Vanveggel, S. ^{[10
]}

Van Eygen, V. ^{[10
]}

Polli, J. ^{[11
]}

de Ruiter, A. ^{[11
]}

Smith, K. ^{[12
]}

Spreen, W. ^{[9
]}

机构：

[1] ViiV Healthcare, Clin Dev, Brentford, England

[2] ViiV Healthcare, Clin Virol, Brentford, England

[3] ViiV Healthcare, Clin Dev, Res Triangle Pk, NC USA

[4] GlaxoSmithKline, Stat, R&D, Collegeville, PA USA

[5] ViiV Healthcare, Global Hlth Outcomes, Brentford, England

[6] ViiV Healthcare, Translat Med Res, Res Triangle Pk, NC USA

[7] GlaxoSmithKline, Clin Pharmacol Modelling & Simulat, Res Triangle Pk, NC USA

[8] ViiV Healthcare, Stat, R&D, Res Triangle Pk, NC USA

[9] ViiV Healthcare, Clin Dev, R&D, Res Triangle Pk, NC USA

[10] Janssen Res & Dev, Clin R&D, Beerse, Belgium

[11] ViiV Healthcare, Global Med Sci, Res Triangle Pk, NC USA

[12] ViiV Healthcare, R&D, Res Triangle Pk, NC USA

来源：

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2020年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

P017

引用

页码：28 / 29

页数：2

共 50 条

[1] Cabotegravir plus rilpivirine every 2 months is noninferior to monthly: ATLAS-2M study
Overton, E. T.
Richmond, G.
Rizzardini, G.
Jaeger, H.
Orrell, C.
Nagimova, F.
Bredeek, F.
Garcia Deltoro, M.
Benn, P. D.
Wang, Y.
Hudson, J.
Margolis, D. A.
Smith, K. Y.
Williams, P. E.
Spreen, W.
HIV MEDICINE, 2020, 21 : 14 - 15
[2] Long-acting cabotegravir plus rilpivirine as maintenance therapy: ATLAS week-48 results
Margolis, D. A.
Swindells, S.
Andrade-Villanueva, J-F
Richmond, G. J.
Rizzardini, G.
Baumgarten, A.
Masia, M. D. M.
Latiff, G.
Pokrovsky, V.
Mrus, J. M.
Huang, J. O.
Hudson, K. J.
Smith, K. Y.
Williams, P.
Spreen, W. R.
HIV MEDICINE, 2019, 20 : 20 - 21
[3] Week 96 efficacy and safety of cabotegravir plus rilpivirine every 2 months in ATLAS-2M Phase IIIb study
Jaeger, Hans
Overton, Edgar
Richmond, Gary
Rizzardini, Giuliano
Andrade-Villanueva, Jaime-Federico
Mngqibisa, Rosie
Hermida, Antonio Ocampo
Thalme, Anders
Benn, Paul
Wang, Yuanyuan
Hudson, Krischan
Margolis, David
Talarico, Christine
Vandermeulen, Kati
Spreen, William
HIV MEDICINE, 2021, 22 : 27 - 28
[4] Cabotegravir plus rilpivirine as long-acting maintenance therapy: LATTE-2 week 48 results
Margolis, D.
Podzamczer, D.
Stellbrink, H-J
Lutz, T.
Angel, J.
Richmond, G.
Clotet, B.
Gutierrez, F.
Sloan, L.
Griffith, S.
St Clair, M.
Dorey, D.
Ford, S.
Mrus, J.
Crauwels, H.
Smith, K.
Williams, P.
Spreen, W.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
[5] Cabotegravir plus rilpivirine long-acting as HIV-1 maintenance therapy: ATLAS Week 96 results
Swindells, S.
Lutz, T.
Van Zyl, L.
Porteiro, N.
Benn, P.
Huang, J.
Harrington, C.
Hove, K.
Ford, S.
Talarico, C.
Chounta, V.
Crauwels, H.
Van Solingen-Ristea, R.
Vanveggel, S.
Margolis, D.
Smith, K.
Vandermeulen, K.
Spreen, W.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 19 - 21
[6] Cabotegravir plus rilpivirine long-acting as HIV-1 maintenance therapy: ATLAS week 96 results
Swindells, Susan
Lutz, Thomas
Van Zyl, Lelanie
Porteiro, Norma
Benn, Paul
Huang, Jenny O.
Harrington, Conn M.
Hove, Kai
Ford, Susan L.
Talarico, Christine L.
Chounta, Vasiliki
Crauwels, Herta
Van Solingen-Ristea, Rodica
Vanveggel, Simon
Margolis, David A.
Smith, Kimberly Y.
Vandermeulen, Kati
Spreen, William R.
Baum, Alexander
INFECTION, 2021, 49 (SUPPL 1) : S7 - S8
[7] Patient-reported outcomes after 152 weeks of HIV maintenance therapy with long-acting cabotegravir plus rilpivirine in the phase IIIb ATLAS-2M study
Chounta, V.
Overton, E.
Noe, S.
Swindells, S.
Negredo, E.
D'Amico, R.
Harrington, C.
Vanveggel, S.
Van Solingen-Ristea, R.
Wang, Y.
Acuipil, C.
Spreen, W.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 72 - 73
[8] ATLAS-2M subanalysis based on prior injection exposure: efficacy, ISRs, and preference of cabotegravir plus rilpivirine every 2 months
Quercia, R. P.
Overton, E. T.
Benn, P. D.
Wang, Y.
Hudson, K. J.
Chounta, V.
Shaefer, M.
Polli, J. W.
Talarico, C.
Cutrell, A.
Margolis, D. A.
Smith, K. Y.
Williams, P. E.
Spreen, W.
HIV MEDICINE, 2020, 21 : 26 - 27
[9] Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
Overton, Edgar T.
Richmond, Gary
Rizzardini, Giuliano
Jaeger, Hans
Orrell, Catherine
Nagimova, Firaya
Bredeek, Fritz
Deltoro, Miguel Garcia
Swindells, Susan
Andrade-Villanueva, Jaime Federico
Wong, Alexander
Khuong-Josses, Marie-Aude
Van Solingen-Ristea, Rodica
van Eygen, Veerle
Crauwels, Herta
Ford, Susan
Talarico, Christine
Benn, Paul
Wang, Yuanyuan
Hudson, Krischan J.
Chounta, Vasiliki
Cutrell, Amy
Patel, Parul
Shaefer, Mark
Margolis, David A.
Smith, Kimberly Y.
Vanveggel, Simon
Spreen, William
LANCET, 2020, 396 (10267): : 1994 - 2005
[10] Long-acting cabotegravir plus rilpivirine for HIV treatment: FLAIR week 96 results
Orkin, C.
Oka, S.
Philibert, P.
Brinson, C.
Bassa, A. C.
Gusev, D.
Degen, O.
Gonzalez Garcia, J.
D'Amico, R.
Dorey, D.
Griffith, S.
Margolis, D. A.
St Clair, M.
Williams, P.
Spreen, W. R.
HIV MEDICINE, 2020, 21 : 14 - 14

← 1 2 3 4 5 →